Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

80%

4 trials in Phase 3/4

Results Transparency

100%

4 of 4 completed trials have results

Key Signals

1 recruiting4 with results

Enrollment Performance

Analytics

Phase 3

4(80.0%)

Phase 1

1(20.0%)

5Total

Phase 3(4)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT03013751Phase 3Completed

A Extension Study of Udenafil in Adolescents

Role: lead

NCT05918211Phase 3Recruiting

Fontan Udenafil Exercise Longitudinal Assessment Trial - 2

Role: lead

NCT03430583Phase 3Completed

Evaluation of Fontan-associated Hepatic Stiffness and the Efficacy of Udenafil in Reducing Liver Stiffness

Role: lead

NCT02741115Phase 3Completed

Fontan Udenafil Exercise Longitudinal Assessment Trial

Role: lead

NCT02201342Phase 1Completed

Pharmacokinetic/Pharmacodynamic Study of Udenafil in Adolescents

Role: lead

All 5 trials loaded